
Quarterly report 2025-Q1
added 05-08-2025
Regulus Therapeutics Net Debt 2011-2026 | RGLS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Regulus Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22 M | -21.8 M | -55.7 M | -26.4 M | -19.5 M | 2.64 M | 6.34 M | 66 M | -16 M | 9.47 M | 89.7 M | 27.1 M | 1.64 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 89.7 M | -55.7 M | 3.19 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 22.57 | 0.04 % | $ 3.74 B | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Akebia Therapeutics
AKBA
|
-133 M | $ 1.41 | -1.4 % | $ 363 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 91.98 | -0.11 % | $ 27.2 B | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.56 | -3.76 % | $ 16.1 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.85 | -1.39 % | $ 9.26 B | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 20.87 | 2.3 % | $ 976 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.17 | -0.24 % | $ 446 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.57 | -0.16 % | $ 3.13 B | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Cabaletta Bio
CABA
|
-76.6 M | $ 3.17 | 2.59 % | $ 319 M | ||
|
Codiak BioSciences
CDAK
|
-39.4 M | - | -55.98 % | $ 2.15 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Avid Bioservices
CDMO
|
17.5 M | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
-188 M | - | - | $ 1.41 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 2.93 | -4.87 % | $ 6.38 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Celldex Therapeutics
CLDX
|
-26.5 M | $ 33.62 | 3.73 % | $ 2.23 B | ||
|
Concert Pharmaceuticals
CNCE
|
-127 M | - | - | $ 401 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 3.92 | 1.03 % | $ 264 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Celsion Corporation
CLSN
|
-7.77 M | - | -6.63 % | $ 13.9 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M |